| ABSTRACT Objective:The use of anti tumor drugs were evaluated in breast cancer patients in hospitals to provide evidences for clinical rational drug use. Methods:206 patients with metastatic breast cancer of a retrospective study were evaluated, according to the drug instructions and clinical practice guidelines. Effectiveness was evaluated according to RECIST 4.03 standards. Safety was evaluated according to the CTACE 4.03 criteria for adverse events. The economic evaluation included the hospitalization costs, drug costs, and anti cancer drug costs for treatment. Results: Efficacy evaluation showed that the objective response rate was 16.0% (33/206), the disease control rate was 65.0% (134/206), the disease progression was 7.8% (16/206), and the unevaluated patients were 27.2% (56/206). The rationale chemotherapy regimen accounted for 80.1% (165/206), the chemotherapy regimen with lack of evidence made up 19.9% (41/206), and patients of route of administration and off label were 4.8% (10/206). The average dose intensity was 89.6%. Most of the adverse drug reactions were mild, and severe adverse drug reaction with more than Grade Ⅲ accounted for 3.0%. The median value of hospitalization costs, treatment cost, and antitumor cost was 7 870, 6 082, 3 983 yuan, respectively. Conclusion: The efficacy and adverse reaction rates of anti tumor drugs in the present study were lower incidence, which might be related to the average dose of chemotherapy regimens being lower than those of the standard of guideline. Therefore, it is necessary to further improve the irrational use of drugs, such as lower dose intensity, lack of evidences for treatment regimens, incorrect route of administration, and inappropriate amount of solvent. |
